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ORIGINAL RESEARCH - CONGENITAL HEART DISEASECONGENITAL
HEART DISEASE
GDF‐15 (Growth Differentiation Factor 15) Is Associated With
Hospitalization and Mortality in Patients With a Fontan Circulation
Sophie L. Meyer, BSc ; Djoeke Wolff, MD, PhD; Floris‐Jan S. Ridderbos, MD; Graziella Eshuis, MD;
Hans Hillege, PhD; Tineke P. Willems, MD, PhD; Tjark Ebels, MD, PhD; Joost P. van Melle, MD, PhD;
Rolf M. F. Berger, MD, PhD
Background— We investigated serial serum levels of GDF‐15 (growth differentiation factor 15) in
Fontan patients and their relation to outcome.
Methods and Results— In this single‐center prospective study of consecutive Fontan patients, serial
serum GDF‐15 measurement and clinical assessment was done at baseline (n=81) and after 2 years
(n=51). The association between GDF‐15 and the combined end point of all‐cause mortality, heart
transplant listing, and Fontan‐related hospitalization was investigated. Median age at baseline was 21
years (interquartile range: 15–28 years). Median GDF‐15 serum levels at baseline were 552 pg/mL
(interquartile range: 453–729 pg/mL). GDF‐15 serum levels correlated positively with age, age at
Fontan initiation, New York Heart Association class, and serum levels of NT‐proBNP (N‐terminal pro‐B‐
type natriuretic peptide) and ɣGT (γ‐glutamyltransferase) and negatively with exercise capacity. During
a median follow‐up of 4.8 years (interquartile range: 3.3–5.5 years), the combined end point occurred in
30 patients (37%). Multivariate Cox regression showed that patients with the highest baseline GDF‐15
(n=20, defined as the upper quartile) had a higher risk of hospitalization or death than the lowest 3
quartiles (hazard ratio [HR], 2.76; 95% CI, 1.27–6.00; P=0.011). After 2 years of follow‐up, patients in
whom serum level of GDF‐15 increased to >70 pg/mL (n=13) had a higher risk of hospitalization or
death than the lowest 3 quartiles (HR, 2.69; 95% CI, 1.03–6.99; P=0.043).
Conclusions— In Fontan patients, elevated serum levels of GDF‐15 are associated with worse
functional status and predict Fontan‐related events. Furthermore, serial measurements showed that an
increase in GDF‐15 serum level was associated with increased risk for adverse outcome.
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Nonstandard Abbreviations and Acronyms
CMR ardiac magnetic resonance
CPET cardiopulmonary exercise testing
EF ejection fraction
GDF‐15 growth differentiation factor‐15
IQR interquartile range
NT‐proBNP N‐terminal pro‐B‐type natriuretic peptide
NYHA New York Heart Association
p   peak oxygen uptake
TGF‐β transforming growth factor β
Patients with a functionally univentricular heart are currently palliated with a sequence of operations
culminating in the Fontan circulation.  The data on long‐term survival remain unsatisfactory because
the nonphysiologic Fontan circulation deteriorates over time, ultimately leading to a state known as
“Fontan failure.” Fontan failure is a state of multiorgan failure with heterogeneous presentation;
significant interindividual differences regarding timing, severity, and mode ; and limited treatment
options.  Insufficient information is available on the exact mechanisms responsible for the failure of the
Fontan circulation and the long‐term risk factors. To date, no conventional heart failure biomarker has
been identified that reliably predicts deterioration and adverse events in this heterogeneous group.
GDF‐15 (growth differentiation factor 15), a cytokine of the TGF‐ß (transforming growth factor ß)
superfamily, is involved in various stress pathways.  Under pathologic conditions, such as
inflammation, tissue hypoxia, and injury, GDF‐15 is upregulated in various organ systems, including the
liver, the kidneys, the pulmonary vascular system, and the cardiovascular system.  Previous
studies have identified that GDF‐15 levels are increased in patients with hepatocellular carcinoma and
cirrhosis  and in patients with chronic failure of the structurally normal heart and that these levels
are of prognostic value for adverse cardiovascular events.  In a mixed cohort of patients with
congenital heart diseases, single GDF‐15 measurements correlated with functional status and
predicted cardiovascular events.  The fact that GDF‐15 is excreted by not only the heart but also




● This study showed that in Fontan patients, elevated serum levels of GDF‐15 (growth differentiation factor
15) are associated with worse functional status.
● GDF‐15 serum levels identified a cohort of Fontan patients at high risk of hospitalization or death.
● Serial measurements of GDF‐15 serum level have an additive benefit in predicting Fontan patients at high
risk for adverse events.
What Are the Clinical Implications?
● These findings serve as the basis for larger scale evaluations into the role of GDF‐15 in the Fontan
population and provide evidence to support the routine use of single and serial GDF‐15 measurements for
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detection and monitoring of Fontan failure, characterized by multiorgan involvement. However, only 1
relatively small cross‐sectional study (n=38) has addressed the value of GDF‐15 in the Fontan
circulation and identified a correlation with systemic ventricular function.  The aim of the current study
was to investigate serial serum GDF‐15 measurements over time in Fontan patients and to relate these
measurements to outcome. We hypothesized that high GDF‐15 serum level or a rise in GDF‐15 serum
level predicts adverse outcomes.
Methods
Data Availability
The data that support the findings of this study are available from the corresponding author on
reasonable request.
Patients
Consecutive patients ≥10 years old with a Fontan circulation who were followed at the Center for
Congenital Heart Disease, University Medical Center Groningen, The Netherlands, between 2012 and
2014 were included. At this center, all Fontan patients undergo standardized follow‐up, including
cardiopulmonary exercise testing (CPET), cardiac magnetic resonance (CMR) examination,
echocardiography, and venipuncture for laboratory measurements every 2 years. Patients were
screened for kidney failure, defined as creatinine levels >200 μmol/L, but none were found. All patients
who had at least 1 venipuncture for laboratory measurement done were included. Exclusion criteria
were CMR, echocardiography, and CPET tests done >2 months from venipuncture and <1 year follow‐
up after baseline venipuncture.
The investigation conforms to the principles outlined in the Declaration of Helsinki. The institutional
ethics committee approved the conduct of this investigation. Informed consent was obtained from all
study participants and/or their parents.
Clinical and Outcomes Assessment
Patient characteristics were collected from medical records, including age, sex, body mass index, body
surface area, New York Heart Association (NYHA) class, cardiac anatomy, type of initial Fontan
operation, follow‐up since both Fontan initiation (bidirectional cavopulmonary shunt or 1‐stage Fontan)
and completion and current cardiac medication use, oxygen saturation measured by pulse oximetry,
and renal function measured by serum creatinine.  Diffusion‐weighted imaging of the liver, a magnetic
resonance imaging–based technique that can be used to detect liver fibrosis and cirrhosis, was done in
a subset of patients and apparent diffusion coefficient values were calculated, as reported previously.
For this study, follow‐up data were collected up to September 1, 2018. The combined end point was
defined as Fontan‐related hospitalization, heart or heart–lung transplantation, listing for these
procedures, and death. Fontan‐related hospitalization was defined as an overnight admission for
cardiac decompensation, arrhythmias, thromboembolic events, Fontan‐associated liver disease,
protein‐losing enteropathy, or a Fontan‐related intervention.
Laboratory Measurements
Venous blood samples were drawn during routine follow‐up. Liver function tests and creatinine and
hemoglobin measurements were performed using standard laboratory techniques. For NT‐proBNP (N‐
terminal pro‐B‐type natriuretic peptide) measurements, the specimens were collected in 4.5‐mL lithium‐
heparin tubes, centrifuged, and directly determined by immunoassay using the Roche Modular E
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was determined by a quantitative sandwich enzyme immunoassay technique using the
electrochemiluminescence immunoassay Elecsys GDF‐15 (Roche Diagnostics) on the Cobas e 801
immunoassay analyzer. For quality control, 2 control measurements were done. The lower limit of
detection for the GDF‐15 assay was 400 pg/mL.
Echocardiography
Transthoracic echocardiography was performed using a commercially available General Electric
ultrasound machine with a 3.5‐MHz probe. A standardized protocol was used that included parasternal,
apical, subcostal, and suprasternal views. For the assessment of diastolic function, the peak early (E)
and late (A) inflow velocities across the dominant atrioventricular valve were measured using a pulsed
Doppler sample on the apical chamber view. Pulsed wave tissue Doppler imaging was used to assess
the peak early (e′) diastolic velocities of the atrioventricular annulus of the nonseptal (free) wall. The
E/e′ ratio and E/A ratio were calculated.
Cardiopulmonary Exercise Testing
CPET was performed on an upright cycle ergometer in children or on a treadmill in adults, as described
previously.  Peak oxygen uptake (p   ) was calculated as the mean of the last 30 seconds during
exercise and was indexed for body weight (p    indexed). The p    as percentage of predicted was
calculated using reference values.  Adequate performance of the CPET was defined as an respiratory
exchange ratio of at least 1.0.  Patients who did not reach this threshold were excluded. The actual
number of patients included for analysis was reported as appropriate.
CMR Acquisition and Analysis
CMR studies were performed on a 1.5‐T system (Magnetom Avanto; Siemens) without sedation, as
previously described.  Imaging analysis was performed using Qmass (v7.6.14.0; Medis Medical
Imaging). The end‐systolic and end‐diastolic blood volumes were calculated from the endocardial
contours; both the volumes of the systemic and hypoplastic ventricle were included. The ejection
fraction (EF) was calculated from end‐diastolic and end‐systolic blood volumes. Cardiac output was
defined as ascending aortic flow. Cardiac index was calculated using body surface area.
Because patients with a pacemaker or claustrophobia were not able to undergo CMR examination,
the actual numbers included for CMR analysis were reported as appropriate.
Statistical Analysis
All continuous variables were tested for normality using the Shapiro–Wilk test and are presented as
mean±SD if parametric tests were used or as median (interquartile range [IQR]) if nonparametric tests
were used. Categorical data were presented as frequency (percentage of total). The distribution of
GDF‐15 was skewed and remained skewed after log, square root, and reciprocal transformation.
Patients were classified according to quartiles of GDF‐15 in concordance with previously published
literature.  Continuous variables stratified by GDF‐15 were analyzed using linear regression,
and differences in categorical variables were evaluated using the χ  Mantel–Haenszel test for trend.
NT‐proBNP had an exponential distribution and thus was log‐transformed for statistical analysis, but
untransformed median and IQR are reported for ease of interpretation. Comparisons between baseline
and follow‐up measurements were done using the paired t test or Wilcoxon signed rank test. Cox
regression analysis was used to perform univariate survival analysis, stratified by baseline GDF‐15
quartiles 1, 2, and 3 versus quartile 4. Multivariate Cox regression was performed with baseline GDF‐15
stratified by quartiles 1, 2, and 3 versus quartile 4 as the independent variable. Specified covariates
were individually adjusted for, and thereafter all variables significantly (P<0.05) associated with







24, 25, 26, 27
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end point–free survival was defined as the time from study inclusion to the occurrence of the first event
(ie, Fontan‐related hospitalization, heart or heart–lung transplant or listing for these procedures, or
death). Event‐free participants were censored at the most recent clinical follow‐up date when event
status was known. Follow‐up time was truncated at 5.5 years from baseline and at 3 years from follow‐
up to ensure sufficient group size for adequate analysis. Because the amount of patients with CPETs
was lower than the total cohort, 2 multivariate models were tested, with and without CPET variables.
The interval change (Δ) between GDF‐15 levels at baseline and at follow‐up, and of all conventional
parameters, was calculated, and patients were classified according to quartiles. Cox regression with all
parameters stratified by quartiles 1, 2,and 3 versus quartile 4 was performed. All analyses were




Eighty‐one patients with a median age of 21 years (IQR: 14.5–27.5 years) were included at baseline, of
whom 32 (40%) were aged <18 years. Median GDF‐15 serum level at baseline was 552.2 pg/mL (IQR:
452.5–728.7 pg/mL). These values are higher than reported GDF‐15 serum levels from healthy controls
of similar age (median: 429 pg/mL)  and slightly lower than GDF‐15 serum levels of patients with
various congenital heart diseases (median: 618 pg/mL) with a median age of 33 years.  The control
measurements of the GDF‐15 analysis showed an intermediate precision of 2.69% (acceptable limit:
<4.6%) and 2.94% (acceptable limit: <4.0%).
Patients in the upper GDF‐15 quartile were significantly older and were more likely than those in
lower quartiles to have an atriopulmonary connection, a higher NYHA class, more β‐blocker use, a
pacemaker, a lower cardiac index, a lower exercise capacity, and higher NT‐proBNP and liver function
parameters (γGT, alanine aminotransferase, alanine aminotransferase/aspartate aminotransferase




Table 1. Baseline Patient Characteristics (Table view)












n (%) 81 (100) 20 (25) 21 (25) 20 (25) 20 (25)  
Age, y 21 (15–
28)
15 (12–17) 21 (16–27) 20 (13–24) 28 (24–35) <0.001










4.7 (3.5–6.6) 4.1 (3.2–5.1) 4.5 (3.1–5.6) 4.8 (3.8–7.7) 0.32
Left ventricular
morphology, n (%)
68 (84) 18 (90) 19 (91) 14 (70) 17 (85) 0.33
Fontan type, n (%)      <0.001
Atriopulmonary
connection/Bjork
16 (20) 0 (0) 2 (10) 3 (15) 11 (55)  
Lateral tunnel 44 (54) 9 (45) 16 (76) 10 (50) 9 (45)  
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21 (26) 11 (55) 3 (14) 7 (35) 0 (0)  
Pacemaker, n (%) 15 (19) 1 (5) 2 (10) 3 (15) 9 (45) 0.001
β‐Blocker use, n
(%)
20 (25) 1 (5) 6 (29) 3 (15) 10 (50) 0.005
History of
arrhythmia, n (%)
22 (27) 1 (5) 3 (14) 5 (25) 13 (65) <0.001
NYHA class, n (%)      0.002
I 35 (43) 12 (60) 11 (52) 9 (45) 3 (15)  
II 36 (44) 7 (35) 10 (48) 9 (45) 10 (50)  















29 (23–33) 27 (21–34) 25 (21–33) 18 (15–21) <0.001




57 (43–66) 64 (56–74) 63 (46–65) 49 (45–60) 0.04




95 (91–97) 93 (90–96) 95 (93–95) 93 (89–95) 0.05
Ea, cm/s (n=55) 66 (55–
78)
66 (60–76) 65 (56–79) 75 (64–83) 50 (43–57) 0.31





9.9 (7.2–12.8) 10.4 (9.1–12.6) 10.0 (8.9–
12.4)
0.30
E/A (n=54) 1.4 (1.1–
1.8)
1.5 (1.1–1.9) 1.4 (1.2–1.7) 1.7 (1.2–1.9) 1.1 (0.8–1.6) 0.08
E/e′ (n=48) 6.1 (4.7–
7.9)








185 (119–223) 175 (142–191) 173 (120–
202)
0.45
NT‐proBNP ng/La 113 (62–
269)
75 (51–109) 116 (64–317) 124 (51–148) 306 (100–
479)
0.005
Creatinine μmol/La 63 (55–
77)
53 (40–64) 61 (55–71) 62 (57–74) 77 (67–85) <0.001
ɣGT, μ/L 59 (39–
103)
54 (33–71) 50 (42–106) 52 (34–76) 94 (66–171) 0.01
AST, μ/L 30 (25–
35)
32 (27–37) 27 (23–31) 30 (27–44) 30 (25–33) 0.62
ALT, μ/L 26 (21–
32)
26 (19–29) 25 (21–32) 29 (19–35) 29 (23–35) 0.03
AST/ALT ratio 1.1 (0.9–
1.4)
1.3 (1.2–1.5) 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.0 (0.8–1.0) 0.002
ADC value,
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Survival status and follow‐up data were available for all 81 patients included at baseline. The
median follow‐up duration from baseline was 4.8 years (IQR: 3.3–5.5 years). The composite end point
occurred in 30 patients (37%): there were 2 deaths, 1 listing for heart transplant, and 27 Fontan‐related
hospitalizations due to cardiac decompensation (n=3), arrhythmia (n=17, 15 atrial and 2 ventricular
arrhythmias), Fontan‐associated liver disease (ie, hepatocellular carcinoma; n=1), severe protein‐losing
enteropathy (n=2), and cardiovascular interventions (n=4). Median time to event was 3.5 years (IQR:
2.6–4.6 years).
Fontan patients with a GDF‐15 serum level in the upper quartile (n=20) were at increased risk for the
combined outcome (P<0.001; Table 2, Figure 1). Although adjustment for age and sex slightly affected
the predictive value, GDF‐15 serum level in the upper quartile remained significantly associated with
outcome (hazard ratio [HR], 3.10; 95% CI, 1.33–7.27; P=0.009). After full adjustment for all variables
significantly associated with outcome in the univariate analysis, upper GDF‐15 quartile remained a
significant predictor of outcome (P=0.011; Table 2). Similarly, when GDF‐15 serum levels were stratified
at the median value, univariate Cox regression analysis revealed a GDF‐15 level above the median
value to also be predictive for adverse outcome (HR: 2.11; 95% CI, 1.01–4.41; P=0.047). In addition,
when analyzed as a continuous value with univariate Cox regression, GDF‐15 baseline serum level
correlated significantly with outcome (per Δ10, HR: 1.40; 95% CI, 1.07–1.82; P=0.014). Finally,
subanalysis excluding all patients with an atriopulmonary connection Fontan did not attenuate the
predictive quality of GDF‐15 at univariate Cox regression (Q4 versus Q1, Q2, and Q3, HR: 3.15; 95%
CI, 1.22–8.12; P=0.018), although in this specific subgroup at multivariate analysis, GDF‐15 did not
remain significantly associated with outcomes. For a full overview of the univariate and multivariate
regression models, see Table S1.














30 (37) 7 (35) 4 (19) 5 (25) 14 (70) 0.001
Death 2 (6) … … … 2 (14)  
Transplant listing 1 (3) … 1 (25) … …  
Cardiac
decompensation
3 (10) … … … 3 (21)  
Arrhythmia 17 (57) 3 (43) 3 (75) 3 (60) 8 (57)  
Protein‐losing
enteropathy
2 (6) 1 (14) … 1 (20) …  
Hepatocellular
carcinoma
1 (3) … … … 1 (7)  
Fontan‐related
procedure
4 (13) 3 (43) … 1 (20) …  
Values are reported as median (interquartile range) or mean (SD), except as noted. Differences across quartiles were analyzed using
linear regression for continuous variables and the χ  Mantel–Haenszel test for trend for categorical variables. Not all patients underwent
cardiovascular magnetic resonance imaging and cardiopulmonary exercise testing; therefore, the exact number of included patients is
indicated at the appropriate variable. ADC indicates apparent diffusion coefficient; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; E/A, ratio of peak early diastolic flow over peak late diastolic flow; E/e′, ratio of peak early diastolic flow over rate of
acceleration of blood across the mitral valve in early diastole; e′, rate of acceleration of blood across the mitral valve in early diastole;
Ea (cm/sec), peak early mitral annular tissue velocity recorded by Doppler tissue imaging; ɣGT, ɣ‐glutamyltransferase; GDF‐15, growth
differentiation factor 15; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; and p   , peak
oxygen uptake.
NT‐proBNP normal values: 42.5–106.4 ng/L (men) and 111.0–215.9 ng/L (women) ; creatinine reference values: 53–106 μmol/L





22-5-2020 GDF‐15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation
https://www.ahajournals.org/doi/epub/10.1161/JAHA.119.015521 8/15
Longitudinal Analysis
Table 2. Baseline GDF‐15 Univariate and Multivariate Outcome Analysis (Table view)
 HR 95% CI P Value
Baseline GDF‐15 quartile 4 vs 1, 2,and 3 (n=81)
Univariate 4.16 2.04–8.43 <0.001
Multivariate model
GDF‐15 quartile 4 vs 1,2,3 2.76 1.27–6.00 0.01
Age, y 0.96 0.89–1.04 0.31
History of arrhythmia 1.09 0.39–3.08 0.87
NYHA class
I    
II 1.61 0.60–3.87 0.32
III 1.47 0.26–3.84 0.54
NT‐proBNP ng/L (log‐transformed) 3.06 1.23–7.61 0.02
For multivariate analysis, all variables (including GDF‐15) were tested using univariate Cox regression; if they were significantly
associated with the outcome (P<0.05), they were included in the multivariate model and removed in backward fashion (removal
criterion P>0.1). See Table S1 for a complete overview of the Cox regression analysis. GDF‐15 indicates growth differentiation factor
15; HR, hazard ratio; NYHA, New York Heart Association; and NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Figure 1. Event‐free survival stratified by GDF‐15 (growth differentiation factor 15) quartiles 1, 2, and 3 (n=61) vs quartile
4 (n=20).
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GDF‐15 measurements from the second outpatient visit were available for 51 patients. The median time
between the first and second visit was 2.1 years (IQR: 1.9–2.25 years). Median GDF‐15 level of the
group did not increase significantly over the course of 2 years (baseline [570 pg/mL; IQR: 451–74)
pg/mL] versus follow‐up [596 pg/mL; IQR: 483–873 pg/mL]; P=0.251). Of the 51 patients, 30 (59%)
remained in the same GDF‐15 quartile, 8 (16%) changed to a lower quartile, and 13 (25%) changed to
a higher quartile. CMR parameters (EF, cardiac index), echocardiography parameters, and functional
parameters (NYHA, CPET) did not worsen significantly. Of all conventional parameters (NYHA class,
EF, cardiac index, p    index, p    predicted percentage, NT‐proBNP, ɣGT), only interval change in
NT‐proBNP correlated significantly with interval change in GDF‐15 (Spearman ρ=0.35, P=0.014). The
composite end point occurred in 17 patients (33%): there was 1 death and 16 Fontan‐related
hospitalizations due to cardiac decompensation (n=1), arrhythmia (n=10, 8 atrial and 2 ventricular
arrhythmias), severe protein‐losing enteropathy (n=2), and cardiovascular interventions (n=3). Median
time from the second measurement time point to event was 1.0 year (IQR: 0.7–1.9 years). Similar to
baseline analysis, at follow‐up, Fontan patients in the highest GDF‐15 quartile remained at higher risk
for the composite outcome than patients in the lower 3 quartiles (HR: 3.19; 95% CI, 1.23–8.28;
P=0.017). Fontan patients with an increase in GDF‐15 serum levels of >70 pg/mL (n=13; ie, the upper
quartile of GDF‐15 interval change between baseline and follow‐up visit) had a higher risk of
hospitalization or death at univariate analysis (HR: 2.69; 95% CI, 1.03–6.99; P=0.043; Figure 2,
Table 3). This association was negated after adjustment for age and sex. Ten patients in the upper
baseline GDF‐15 quartile did not have an increase in GDF‐15 over time. Of these, 5 (50%) had an end
point occurrence. All end points were atrial arrhythmias. Of the 34 patients who did not experience the
primary outcome, 5 (15%) had an increase of GDF‐15 of >70 pg/mL, as opposed to 8 of the 17 (47%)
who did experience the primary outcome.
2 2
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Figure 2. Event‐free survival stratified by GDF‐15 (growth differentiation factor 15) interval change quartiles 1, 2, and 3
(n=38) vs quartile 4 (n=13).
Table 3. Interval Change Outcome Analysis (n=51) (Table view)
 HR 95% CI P Value
Univariate Cox regression
GDF‐15 interval change
Q4 vs Q1,Q2, and Q3
2.69 1.03–6.99 0.04
NYHA class worsening, yes 1.90 0.45–8.55 0.37
Ejection fraction interval change (n=26)
Q1 vs Q2, Q3, and Q4
2.95 0.79–11.04 0.11
Cardiac index interval change (n=26)
Q1 vs Q2, Q3, and Q4
4.34 0.87–21.67 0.07
p    indexed interval change (n=36)
Q1 vs Q2, Q3, and Q4
1.26 0.35–4.58 0.73
p    predicted interval change (n=36)
Q1 vs Q2, Q3, and Q4
1.91 0.62–5.84 0.26
NT‐proBNP interval change
Q4 vs Q1, Q2, and Q3
3.48 1.34–9.05 0.01
ɣGT interval change




Q4 vs Q1, Q2, and Q3
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Discussion
This study is the first to evaluate serial measurements of the circulating biomarker GDF‐15 and its
prognostic value in children and adults with a Fontan circulation. GDF‐15 serum levels were associated
with functional status and measures of liver disease. Furthermore, GDF‐15 serum levels independently
predicted adverse outcomes. This study is the first showing that serial biomarker measurement is of
additional value in predicting outcome in the Fontan population.
The attrition of the nonphysiologic Fontan circulation over time is well recognized.  However, the
time course of developing Fontan failure and its heterogeneous presentation involving various organ
systems is still unpredictable and poorly understood. Early identification of patients at increased risk of
deterioration is key to prevent or slow progression and yet has proven to be difficult. To date, studies
focusing on identifying circulating biomarkers for Fontan failure have been done cross‐sectionally,
accepting the limitations this approach inevitably brings.  In the current prospective study with serial
measurements, median GDF‐15 serum levels in Fontan patients were higher than GDF‐15 serum levels
reported in healthy controls of similar age.  Furthermore, GDF‐15 serum levels in this study were
slightly lower than median levels previously reported in patients with a variety of different congenital
heart diseases.  Because GDF‐15 serum levels increase with age independent of cardiac issues,
the latter might be explained by the fact that median age in the current study was lower than in the
referred studies.
We found that in Fontan patients, GDF‐15 serum levels were associated with functional status.
GDF‐15 correlated positively with NYHA class, as has been reported previously in studies in patients
with various congenital heart diseases. However, these studies failed to differentiate between various
subtypes of congenital heart disease.  In the current study, lower peak oxygen uptake was
associated with increased GDF‐15 serum levels. This is in contrast to Eindhoven et al,  who, in a
cohort of patients with various types of congenital heart diseases, were able to detect a significant
association between workload and GDF‐15 but not with peak oxygen uptake. This might have been due
to the smaller sample size (n=40). The significant increase of CPET values over the course of 2 years
is remarkable but can be explained by the young age of the current cohort, representing a natural
increase in muscle mass and thus oxygen utilization potential up to the age of approximately 20 years,
in line with previously published reference values.
In this study, GDF‐15 did not correlate with ventricular EF, as opposed to the findings of Raedle‐
Hurst et al,  who showed GDF‐15 levels significantly higher in patients with an EF <50% compared
with those with an EF >50%. The patient cohort in the current study consisted of relatively young
Fontan patients with a homogenously well‐preserved ventricular function, which might explain these
seemingly contradictory findings. Nevertheless, patients in the upper GDF‐15 quartile had a significantly
worse overall functional status. This finding again highlights that Fontan failure and ventricular failure
are not synonymous.
NT‐proBNP showed a significant positive correlation with GDF‐15, which is in accordance with
previous studies in both congenital and other heart diseases.  Furthermore, GDF‐15 serum
levels correlated positively with measures suggestive for Fontan‐associated liver disease (γGT, alanine
aminotransferase, alanine aminotransferase/aspartate aminotransferase ratio, apparent diffusion
coefficient values), suggesting that GDF‐15 may to some degree reflect the functional status of the liver
in Fontan patients.  Whereas NT‐proBNP and γGT are organ‐specific biomarkers, GDF‐15 is
secreted by various organs, including both the heart and the liver, in response to stress.  Because the
γGT indicates γ‐glutamyltransferase; GDF‐15, growth differentiation factor 15; HR, hazard ratio; NYHA, New York Heart
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Fontan circulation has a detrimental effect on various organs, a biomarker reflecting this state of
multiorgan failure, such as GDF‐15, might prove invaluable.
This study is the first showing that high GDF‐15 levels were predictive for death and Fontan‐related
adverse events, independent of age, sex, surgical history, functional parameters, imaging parameters,
and other laboratory markers. The number of hospitalizations due to Fontan‐related morbidities in this
study was substantial, highlighting that even relatively young Fontan patients with apparently well‐
preserved functional status are at risk for adverse events. Event‐free survival in Fontan patients has
been described to be as low as 29% at 25 years,  and Fontan patients with an associated morbidity
have been reported to have a 36‐fold increase in the risk of subsequent Fontan takedown, heart
transplantation, or death.  With this study, GDF‐15 has been shown to be an important parameter that
is able to predict the occurrence of these morbidities. GDF‐15 serum levels might be a useful tool for
timely detection of patients at risk for morbidities, allowing early adaptation of treatment strategies,
including potential interventions, aiming at prevention or delaying decline into Fontan failure.
In the longitudinal analysis, patients in whom GDF‐15 levels increased >70 pg/mL during the 2‐year
follow‐up had an increased risk of adverse events. This risk could not be predicted by a change in
traditional follow‐up parameters in Fontan patients, such as p    and CMR parameters. When
excluding patients with an atriopulmonary Fontan type, GDF‐15 remained significantly associated with
outcomes at univariate analysis. This observation indicates that the correlation is not solely driven by
the atriopulmonary connection type of Fontan circulation, which may be not representative for
contemporary Fontan patients who are predominantly treated with lateral tunnel or extracardiac type of
Fontan circulation.
The patient cohort investigated in the current study, although larger than in previous studies, is still
relatively small, limiting the power of extensive multivariable analyses, and includes the risk of overfit of
the multivariate models, which consequently should be interpreted with care. Nevertheless, the
prospective, standardized nature of this study makes it unique and ensures adequate and unbiased
representation of Fontan patients in the current era. The number of hard end points (ie, all‐cause
mortality or heart or heart–lung transplants and listings) in this study was low, which might be explained
by the young median age and the overall preserved functional status of the studied cohort. To optimize
outcome analysis, we chose a combined end point of mortality, heart–lung transplant and listing, and
Fontan‐related hospitalization, in line with comparable studies.
The findings of the current study should be confirmed in another independent and larger cohort of
Fontan patients before GDF‐15 serum levels can be used in clinical decision‐making in Fontan patients.
In conclusion, in patients with a Fontan circulation, elevated serum levels of GDF‐15 are associated
with worse functional status and are predictive for adverse outcomes. Furthermore, an increase in
GDF‐15 over time is associated with increased risk of adverse outcomes; however, the additive value of
serial measurements requires validation in a larger and independent cohort.
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